Gwo-Yaw Ho

Projects

Projects per year 2019 2023 2030

• 1 Not started
• 3 Finished
• 6 Active

Projects per year

Search results

• Active

  Developing interferon epsilon as a novel immunotherapy for ovarian cancer: identification of an optimal formulation for enhanced efficacy and tolerability.

  Campbell, N. (Primary Chief Investigator (PCI)), Hertzog, P. (Chief Investigator (CI)), Gearing, J. (Associate Investigator (AI)) & Ho, G.-Y. (Associate Investigator (AI))

  1/07/25 → 30/06/28

  Project: Research

• CATALINA-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women with Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6.

  Ho, G.-Y. (Primary Chief Investigator (PCI))

  11/04/25 → 10/04/30

  Project: Research

• Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinumbased chemotherapy plus bevacizumab (GLORIOSA)

  Ho, G.-Y. (Primary Chief Investigator (PCI))

  21/09/23 → 20/09/28

  Project: Research

• Interferon epsilon: a new localised immunotherapy for ovarian cancer

  Campbell, N. (Primary Chief Investigator (PCI)), Hertzog, P. (Chief Investigator (CI)) & Ho, G.-Y. (Chief Investigator (CI))

  United States Department of Defense (DOD), US Army Medical Research Acquisition Activity

  1/07/23 → 30/06/26

  Project: Research

• A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, versus Investigator’s Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  Ho, G.-Y. (Primary Chief Investigator (PCI))

  22/05/23 → 21/05/28

  Project: Research

• The EPOCH Study - Phase II open labelled study investigating the use of single agent eribulin and eribulin in combination with pembrolizumab in relapsed tubo-ovarian or uterine carcinosarcoma

  Ho, G.-Y. (Primary Chief Investigator (PCI))

  14/04/23 → 13/04/28

  Project: Research

• Not started

  Personalised T-cell receptor therapy for immunological "cold" cancers

  Ho, G.-Y. (Primary Chief Investigator (PCI)), Faridi, P. (Chief Investigator (CI)), Nguyen, T. (Chief Investigator (CI)) & Ooi, J. (Chief Investigator (CI))

  Project: Research

• Finished

  Characterisation of DNA repair antibody DX-1 and DX-3 in autoimmune vasculitis and immunologically cold ovarian cancer

  O'Sullivan, K. (Primary Chief Investigator (PCI)), Ho, G.-Y. (Chief Investigator (CI)) & Ooi, J. (Chief Investigator (CI))

  2/01/23 → 30/06/23

  Project: Research

• Using the power of cord blood stem cells to humanize mice for effective cancer immunotherapy research

  Greenall, S. (Primary Chief Investigator (PCI)), Watt, A. (Chief Investigator (CI)), Ho, G.-Y. (Chief Investigator (CI)), Segelov, E. (Chief Investigator (CI)), O'Keeffe, M. (Associate Investigator (AI)) & Jenkin, G. (Associate Investigator (AI))

  1/01/20 → 31/12/21

  Project: Research

• A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance with Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)

  Frentzas, S. (Primary Chief Investigator (PCI)) & Ho, G.-Y. (Primary Chief Investigator (PCI))

  20/09/19 → 19/09/24

  Project: Research